SecBot SecBot
SECBOTREPLAY Home › Report › NVCR

NVCR · FDA rejects Optune Mya PMA

NovoCure Ltd · 8-K filed Nov 9, 2026 at 06:59 ET

At the news

BEARISHIMPACT 6/10

8-K filed Nov 9, 2026 at 06:59 ET

NovoCure received a Not Approvable Letter from the FDA for its PMA application for Optune Mya to treat brain metastases from non-small cell lung cancer. The FDA cited uncertainty around clinical benefit but raised no safety concerns. The company plans to meet with the FDA to explore options that would not require additional clinical studies, but there is no assurance of eventual approval.

  • FDA issued a Not Approvable Letter for Optune Mya PMA for brain metastases from non-small cell lung cancer
  • FDA determined uncertainty around the degree of clinical benefit prevented approval
  • FDA did not raise concerns related to the safety profile of Optune Mya
  • NovoCure plans to meet with the FDA to explore options that would not require additional clinical studies

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access